Statements from the AGA Institute detailing preferred approaches to specific medical problems or issues based on the most current available data.
The AGA Institute policy and position statements are freely available without a subscription to the online journal.
If you would like to suggest a topic for guideline development please contact:
Jennifer Conte, Director of Clinical Practice
Phone: (301) 941-2641
Fax: (301) 654-5920
E-mail: JConte@gastro.org
This Medical Position Statement has been developed under the aegis of the Clinical Practice Committee of the AGA Institute. It provides preferred approaches to specific medical problems or issues. The statements herein are derived from the data available at the time of their creation and may need to be modified as new information is generated. Unless otherwise stated, these statements are intended for adult patients. The strength of the evidence upon which the statements are based is noted, with prospective, randomized, controlled trials being the strongest. When adequate data are absent, expert consensus may be used and will be identified as such. This document is not to be construed as a standard of care. All decisions regarding the care of a patient should be made by the physician in consideration of all aspects of the patient's specific medical circumstances.
IMPORTANT! Please note that three Medical Position Statements reference Zelnorm (tegaserod), which has been withdrawn from the market due to serious cardiovascular adverse events, including angina, heart attacks, and stroke. See the U.S. Food and Drug Administration (FDA) Web site for more information: http://www.fda.gov/medwatch/safety/2007/safety07.htm#Zelnorm. The AGA Institute Medical Position Statements referencing Zelnorm include:
